Opioid-sparing effect, but limited analgesic efficacy, with preop gabapentinoids in THA .
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2022;10(10):9 BMC Musculoskelet Disord. 2016 Aug 30;17(1):373Seven randomized controlled trials were included in this meta-analysis evaluating the efficacy and safety of preoperative gabapentin and pregabalin for postoperative analgesia following total hip arthroplasty. In all studies, gabapentin and/or pregabalin were compared to either placebo or no intervention. Pooled results demonstrated significantly lower cumulative morphine consumption with gabapentin compared to control up to 24 hours after surgery, and with pregabalin compared to control up to 48 hours after surgery. In contrast, pooled pain scores at rest or on mobilization did not demonstrate significantly lower scores with either gabapentin or pregabalin compared to control. In fact, pain scores during mobilization after 48 hours were significantly higher among gabapentin groups compared to control groups.
Were the search methods used to find evidence (original research) on the primary question or questions stated?
Was the search for evidence reasonably comprehensive?
Were the criteria used for deciding which studies to include in the overview reported?
Was the bias in the selection of studies avoided?
Were the criteria used for assessing the validity of the included studies reported?
Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?
Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?
Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?
How would you rate the scientific quality of this evidence?
Oui = 1
Incertain = 0,5
Non pertinent = 0
Non = 0
L'évaluation des critères de rapport permet d'évaluer la transparence avec laquelle les auteurs rapportent les caractéristiques méthodologiques et les caractéristiques de l'essai dans la publication. L'évaluation est divisée en cinq catégories qui sont présentées ci-dessous.
4/4
Introduction
4/4
Accessing Data
3/4
Analysing Data
4/4
Results
1/4
Discussion
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
L'indice de fragilité est un outil qui aide à l'interprétation des résultats significatifs, en fournissant une mesure de la force d'un résultat. L'indice de fragilité représente le nombre d'événements consécutifs qui doivent être ajoutés à un résultat dichotomique pour que le résultat ne soit plus significatif. Un petit nombre représente un résultat plus faible et un grand nombre un résultat plus fort.
Pourquoi cette étude était-elle nécessaire maintenant ?
One of the most important areas of research regarding perioperative treatment of patients undergoing total hip arthroplasty is postoperative analgesia. Patient-controlled analgesia with opioids remains a standard method of analgesia, although the undesirable side-effects of opioids have led to an emphasis on trying to limit their administration to only rescue analgesia and improve primary treatment. Gabapentinoids, such as gabapentin and pregabalin, have been suggested as medications with possible analgesic efficacy in these patients.
Quelle était la principale question de recherche ?
What are the efficacy and safety profiles of preoperative gabapentin and pregabalin, compared to control, for analgesia following total hip arthroplasty?
- Pooled cumulative morphine consumption was significantly lower among gabapentin groups compared to control after 24h (MD -2.65 [95%CI -3.67, -1.63]; p<0.001) but not 48h (MD 0.00 [95%CI -7.69, 7.69]; p=1.000), while it was significantly lower for pregabalin compared to control after both 24 (MD -19.42 [95%CI -11.72, -3.93]; p<0.001) and 48h (MD -33.02 [95%CI -45.86, -20.19]; p<0.001).
- VAS pain at rest and at 24h did not significantly differ between gabapentin and control (MD 0.32 [95%CI -0.03, 0.67]; p=0.076), and pregabalin and control (MD -3.05 [95%CI -11.63, 5.53]; p=0.486). VAS pain at rest was significantly higher with gabapentin compared to control after 48h (MD 0.41 [95%CI 0.00-0.81]; p=0.049).
- VAS pain with mobilization between gabapentin and control did not significantly differ after 24h (MD 0.72 [95%CI -0.23, 1.66]), and was significantly higher among gabapentin groups after 48h (MD 1.90 [95%CI 0.04-3.75]; p=0.045). No significant difference in VAS pain with mobilization between pregabalin and control was observed after 24h (MD -0.78 [95%CI -6.91, 5.35]; p=0.803).
- No significant difference between gabapentin/pregabalin groups overall and control groups was observed in the incidences of vomiting (RR 0.95 [95%CI 0.47-1.92]), dizziness (RR 0.82 [95%CI 0.51-1.33]), or pruritus (RR 0.89 [95%CI 0.57-1.39]). A significantly lower incidence of nausea was observed with gabapentin/pregabalin groups compared to control (RR 0.49 [95%CI 0.27-0.92]).
De quoi dois-je me souvenir en priorité ?
In total hip arthroplasty, an opioid-sparing effect was observed with preoperative gabapentin up to 24 hours after surgery, and with preoperative pregabalin up to 48 hours after surgery. However, neither treatment provided a significant benefit compared to the control group for pain at rest or on movement. In contrast, pooled pain scores during movement were actually higher in gabapentin groups compared to control groups after 48 hours.
Comment cela affectera-t-il les soins prodigués à mes patients ?
While there may be a short-term reduction in opioid requirement with the use of either gabapentin or pregabalin following total hip arthroplasty, these interventions do not appear to significantly reduce short-term pain scores in patients. Therefore, their role in postoperative analgesia following total hip arthroplasty should be scrutinized based on the currently available data. It is important to note limitations of the available body of evidence, as only 2-3 studies were available to separately assess the efficacy and safety of gabapentin and pregabalin each indicating the need to further large randomized controlled trials.
AVIS DE NON-RESPONSABILITÉ
Le contenu de cette page est fourni à titre d'information uniquement et n'est pas destiné à remplacer un avis médical, un diagnostic ou un traitement professionnel. Si vous avez besoin d'un traitement médical, demandez toujours l'avis de votre médecin ou rendez-vous au service des urgences le plus proche. Les opinions, croyances et points de vue exprimés par les individus sur le contenu de cette page ne reflètent pas les opinions, croyances et points de vue d'OrthoEvidence.
0 de 4 articles mensuels GRATUITS débloqués
